REGISTER
Dr. Geoffrey Liu at WCLC 2025
Dr. Geoffrey Liu at WCLC 2025 is examined through new evidence rather than broad claims. It distills the central data on WCLC, MD, TRUST-II into a clear account of the article's most important conclusions.

MedJ Takes You to WCLC 2025

Geoffrey Liu, MD, Princess Margaret Cancer Centre in Canada presented updated data from the TRUST-II study, revealing the breakthrough efficacy and favorable safety profile of taletrectinib in treating ROS1-positive NSCLC. He highlighted its exceptional potential to overcome drug-resistant mutations and strong CNS penetration, marking a new milestone in ROS1-targeted therapy.

0
0
Loading